Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19042986 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | January 2025 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19020776 | CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTAT | January 2025 | March 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 18868756 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | November 2024 | April 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18768367 | BENZOPYRIMIDINE COMPOUNDS AND USE THEREOF | July 2024 | January 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18743634 | HETEROARYL AZOLE COMPOUND AND PEST CONTROL AGENT | June 2024 | February 2025 | Allow | 8 | 0 | 0 | No | No |
| 18679720 | FORMS OF ATICAPRANT | May 2024 | August 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18650207 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | April 2024 | July 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18589841 | HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | February 2024 | May 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18443959 | COMPOUND OR SALT THEREOF AND LIPID PARTICLES | February 2024 | March 2025 | Allow | 13 | 0 | 0 | Yes | No |
| 18440166 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | February 2024 | April 2025 | Allow | 14 | 2 | 1 | Yes | No |
| 18413842 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | January 2024 | January 2025 | Allow | 12 | 2 | 1 | Yes | No |
| 18395130 | PYRAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AS CK2 INHIBITORS | December 2023 | March 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18571452 | Cancer Treatment | December 2023 | March 2025 | Allow | 15 | 1 | 1 | Yes | No |
| 18315526 | COMPOUNDS AND USES THEREOF | May 2023 | July 2024 | Allow | 14 | 1 | 1 | Yes | No |
| 18304202 | SYNTHESIS OF NIROGACESTAT | April 2023 | January 2025 | Allow | 21 | 3 | 1 | Yes | No |
| 18029177 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | March 2023 | January 2025 | Allow | 22 | 0 | 0 | Yes | No |
| 18191247 | ORALLY BIOAVAILABLE, BRAIN-PENETRANT COMPOUND WITH SELECTIVITY FOR THE CANNABINOID TYPE 2 RECEPTOR WITH POTENTIAL USE TOWARDS VISCERAL PAIN MANAGEMENT AND NEURODEGENERATIVE DISORDERS | March 2023 | March 2024 | Allow | 12 | 1 | 1 | No | No |
| 18119776 | REHYDRATION COMPOSITION AND METHOD OF USE | March 2023 | April 2025 | Allow | 25 | 4 | 0 | Yes | No |
| 18178961 | FORMS OF ATICAPRANT | March 2023 | August 2023 | Allow | 6 | 0 | 0 | Yes | No |
| 18115058 | BLOCKADE OF CHEMOKINE (C-C MOTIF) RECEPTOR 2 DURING FLUID RESUSCITATION | February 2023 | October 2024 | Abandon | 19 | 2 | 0 | No | No |
| 18171831 | USES OF BUPIVACAINE MULTIVESICULAR LIPOSOMES AS STELLATE GANGLION BLOCK | February 2023 | June 2025 | Allow | 28 | 3 | 1 | Yes | No |
| 18169016 | CRYSTALLINE PROSTACYCLIN (IP) RECEPTOR AGONIST AND USES THEREOF | February 2023 | May 2024 | Allow | 15 | 1 | 0 | No | No |
| 18169155 | METHODS OF ADMINISTERING CANNABINOIDS | February 2023 | June 2025 | Allow | 28 | 4 | 1 | Yes | Yes |
| 18162205 | APPLICATION OF DIPYRRINATO-IRIDIUM COMPLEXES IN ANTI-TUMOR AND ANTI-BACTERIAL THERAPY | January 2023 | August 2024 | Allow | 19 | 1 | 0 | No | No |
| 18162365 | IRAK DEGRADERS AND USES THEREOF | January 2023 | May 2024 | Allow | 15 | 1 | 0 | No | No |
| 18162092 | INTRAVENEOUS DOFETILIDE TO REDUCE THE RISK OF DEVELOPING AF/AFL POST CORONARY BYPASS SURGERY | January 2023 | March 2025 | Allow | 25 | 2 | 0 | Yes | Yes |
| 18160866 | STABLE PHARMACEUTICAL COMPOSITION OF TOPIRAMATE | January 2023 | February 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18100754 | SQUALAMINE CRYSTALLINE POLYMORPHS | January 2023 | July 2024 | Abandon | 18 | 1 | 1 | No | No |
| 18090024 | STABLE PHARMACEUTICAL COMPOSITION OF NIMODIPINE | December 2022 | March 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18068857 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | December 2022 | April 2024 | Allow | 16 | 1 | 0 | Yes | No |
| 18002080 | SMALL MOLECULE MODULATORS OF IL-17 | December 2022 | June 2025 | Allow | 30 | 0 | 0 | Yes | No |
| 18064080 | BICYCLIC AMINES AS CDK2 INHIBITORS | December 2022 | December 2023 | Allow | 13 | 0 | 1 | No | No |
| 18078785 | STAT3 DEGRADERS AND USES THEREOF | December 2022 | October 2024 | Abandon | 22 | 2 | 1 | Yes | No |
| 18060108 | Methods To Treat Cancer With AMXT 1501 and DFMO | November 2022 | April 2025 | Abandon | 28 | 3 | 0 | Yes | No |
| 18055146 | TREATMENT FOR EPILEPTIC SEIZURES | November 2022 | April 2024 | Abandon | 17 | 1 | 1 | No | No |
| 17962714 | Methods Of Treating Multiple Sclerosis | October 2022 | March 2025 | Allow | 29 | 3 | 1 | Yes | No |
| 17951696 | TREATMENT OF HUMAN PAPILLOMAVIRUS-ASSOCIATED CANCERS BY PD-L1 INHIBITORS | September 2022 | February 2024 | Abandon | 16 | 1 | 0 | No | No |
| 17939703 | USE OF CANNABINOID COMPOUNDS TO TREAT OR PREVENT FUNGAL GROWTH OF C. ALBICANS | September 2022 | January 2024 | Abandon | 16 | 0 | 1 | No | No |
| 17929320 | RESVERATROL COMPOSITION, PREPARATION METHOD AND APPLICATION THEREOF | September 2022 | August 2024 | Abandon | 23 | 2 | 1 | No | No |
| 17795516 | MULTI-TARGET TYROSINE KINASE INHIBITOR | July 2022 | June 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17854591 | PROCESS FOR PREPARING NITRILE INTERMEDIATES FOR NITROGEN-CONTAINING CHELATORS | June 2022 | January 2024 | Abandon | 18 | 0 | 1 | No | No |
| 17786792 | COMPOUND MODULATORS OF STING | June 2022 | May 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17785239 | SELECTIVE CDK 4/6 INHIBITOR CANCER THERAPEUTICS | June 2022 | January 2025 | Allow | 32 | 1 | 0 | Yes | No |
| 17825260 | COMPOSITION OF ACYLETHANOLAMIDES FROM OLIVE OIL FATTY ACIDS | May 2022 | May 2024 | Allow | 24 | 1 | 1 | No | No |
| 17756545 | FUSED PYRIDINE RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | May 2022 | April 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17732717 | PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME | April 2022 | May 2025 | Allow | 37 | 0 | 0 | Yes | No |
| 17769389 | FLUORINE-CONTAINING PYRIMIDINE COMPOUND AND MANUFACTURING METHOD FOR SAME | April 2022 | April 2025 | Allow | 36 | 0 | 0 | Yes | No |
| 17761014 | METHODS AND COMPOSITIONS FOR TREATING PAIN AND OTHER EPH RECEPTOR-ASSOCIATED CONDITIONS | March 2022 | June 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17686556 | CYCLE WATER TREATMENT PROCESS FOR ETHLYENE EPOXIDATION | March 2022 | November 2023 | Allow | 20 | 1 | 0 | No | No |
| 17632065 | HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | February 2022 | February 2025 | Allow | 37 | 0 | 0 | Yes | No |
| 17292690 | USE OF 3-O-SULFAMOYLOXY-7Beta-METHYL-D-HOMO-6-OXAESTRA-1,3,5(10),8(9)-TETRAEN-17A-ONE TO TREAT BREAST CANCER | January 2022 | September 2024 | Allow | 40 | 0 | 0 | Yes | No |
| 17584577 | HEXASUBSTITUTED BENZENES, SURFACES MODIFIED THEREWITH, AND ASSOCIATED METHODS | January 2022 | February 2025 | Allow | 37 | 0 | 0 | Yes | No |
| 17624182 | IBUPROFEN ESTER PRODRUG, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND APPLICATION | December 2021 | April 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17554792 | BIOORTHOGONAL COMPOSITIONS | December 2021 | February 2025 | Allow | 38 | 3 | 1 | Yes | No |
| 17614941 | BENZOTRIAZOLE DERIVATIVE | November 2021 | January 2025 | Allow | 38 | 0 | 0 | Yes | No |
| 17610031 | METFORMIN COMPLEXES WITH TRANSITION METALS AND P GROUP ELEMENTS | November 2021 | February 2025 | Allow | 39 | 3 | 1 | Yes | No |
| 17609874 | BCL-2 INHIBITORS FOR USE IN THE TREATMENT OF A BCL-2 MEDIATED CANCER CARRYING THE GLY101VAL MUTATION | November 2021 | March 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17599806 | AZAAROMATIC AMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | October 2021 | November 2024 | Allow | 38 | 0 | 1 | Yes | No |
| 17442173 | Prophylactic or Therapeutic Agent for Cancer | September 2021 | March 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17442064 | SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | September 2021 | October 2024 | Allow | 37 | 0 | 0 | No | No |
| 17440872 | INDAZOLES AS LRRK2 INHIBITORS | September 2021 | February 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17477924 | METHODS OF TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA USING DEUTERATED DEXTROMETHORPHAN AND QUINIDINE | September 2021 | March 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17430312 | Agent for Eliminating Pluripotent Stem Cells | August 2021 | January 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17392036 | BENZOTHIAZOLE AND RELATED COMPOUNDS | August 2021 | April 2025 | Allow | 44 | 0 | 1 | Yes | No |
| 17376963 | APOPTOSIS-INDUCING AGENTS | July 2021 | January 2025 | Allow | 42 | 1 | 0 | Yes | No |
| 17311627 | HETEROCYCLIC COMIPOUND AS CDK-HDAC DUAL PATHWAY INHIBITOR | June 2021 | March 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17309494 | Heterocyclic Compound as CDK-HDAC Double-Channel Inhibitor | June 2021 | March 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17332687 | COMPOSITIONS, METHODS AND SYSTEMS FOR THE TREATMENT OF CUTANEOUS DISORDERS | May 2021 | June 2025 | Abandon | 49 | 2 | 1 | Yes | No |
| 17297198 | NOVEL 4-CARBONYLAMINO-4-PHENYLPYRIMIDINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | May 2021 | September 2024 | Allow | 40 | 1 | 1 | No | No |
| 17295181 | Methods of Treating Acute HCV | May 2021 | December 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17289761 | NEW TETRAHYDROPYRIMIDODIAZEPIN AND TETRAHYDROPYRIDODIAZEPIN COMPOUNDS FOR TREATING PAIN AND PAIN RELATED CONDITIONS | April 2021 | September 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17289963 | METHOD OF ENHANCING IMMUNE-BASED THERAPY | April 2021 | March 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17290150 | DRUG COMPOSITIONS | April 2021 | December 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17289786 | READY TO USE INTRAVENOUS INFUSION OF BRIVARACETAM OR SALT THEREOF | April 2021 | March 2025 | Abandon | 47 | 1 | 1 | Yes | No |
| 17289913 | USE OF TIVOZANIB TO TREAT SUBJECTS WITH REFRACTORY CANCER | April 2021 | November 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17290045 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | April 2021 | January 2025 | Allow | 45 | 1 | 1 | No | No |
| 17289794 | 3-(1,2,3,6-TETRAHYDROPYRIDIN-2-YL) PYRIDINE GLUTARATE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF | April 2021 | December 2024 | Allow | 44 | 1 | 1 | Yes | No |
| 17289008 | A LIQUID INJECTABLE COMPOSITION | April 2021 | May 2025 | Allow | 48 | 3 | 1 | Yes | No |
| 17288721 | CYCLODEXTRIN-BASED FORMULATION OF A BCL-2 INHIBITOR | April 2021 | February 2025 | Abandon | 46 | 2 | 1 | No | No |
| 17287548 | NEW ANTHELMINTIC COMPOUNDS | April 2021 | February 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17287356 | FEED ADDITIVE FOR CATTLE COMPRISING N-ACETYL-L-TRYPTOPHAN AS ACTIVE INGREDIENT | April 2021 | August 2024 | Allow | 40 | 2 | 0 | No | No |
| 17286818 | INDANE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | April 2021 | April 2024 | Allow | 36 | 1 | 0 | No | No |
| 17286693 | BETA-CATENIN AND B-CELL LYMPHOMA 9 (BCL9) INHIBITORS | April 2021 | July 2024 | Allow | 39 | 1 | 0 | Yes | No |
| 17285653 | Co-Crystals Comprising Levothyroxine And A Dicarboxylic Acid | April 2021 | March 2024 | Allow | 35 | 0 | 1 | Yes | No |
| 17281251 | PD-L1 ANTAGONIST COMPOUND | March 2021 | June 2024 | Allow | 38 | 1 | 1 | Yes | No |
| 17281481 | OXIDE CATALYST AND METHOD FOR PRODUCING UNSATURATED NITRILE | March 2021 | March 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17206044 | USE OF A CATHEPSIN S INHIBITOR AGAINST THE FORMATION OF ANTI-DRUG ANTIBODIES | March 2021 | May 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17277562 | PHARMACEUTICAL COMPOSITION OF MDM2 INHIBITOR AND USE THEREOF FOR PREVENTING AND/OR TREATING DISEASE | March 2021 | September 2024 | Allow | 42 | 2 | 1 | Yes | No |
| 17200743 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | March 2021 | April 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17185206 | CRYSTALLINE FORMS OF AN NK-1 ANTAGONIST | February 2021 | April 2024 | Allow | 38 | 1 | 0 | No | No |
| 17271531 | HETEROARYL AZOLE COMPOUND AND PEST CONTROL AGENT | February 2021 | August 2024 | Allow | 42 | 1 | 1 | No | No |
| 17271424 | CRYSTAL OF PYRAZOLO[3,4-D]PYRIMIDINE | February 2021 | June 2024 | Allow | 39 | 1 | 0 | No | No |
| 17269577 | CAPSAICIN SEQUENTIAL DOSING METHOD FOR TREATMENT OF KNEE JOINT PAIN | February 2021 | November 2024 | Abandon | 45 | 2 | 0 | No | No |
| 17269811 | SUCCINATE AND FUMARATE ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | February 2021 | June 2024 | Allow | 40 | 1 | 1 | Yes | No |
| 17269725 | N-SUBSTITUTED-1H-1,2,4-TRIAZOLE-3-CARBOXAMIDES, ANALOGUES THEREOF, AND METHODS OF TREATMENT USING SAME | February 2021 | April 2024 | Allow | 38 | 1 | 0 | No | No |
| 17266474 | PRMT5 INHIBITORS | February 2021 | October 2023 | Allow | 32 | 0 | 0 | No | No |
| 17266075 | Process for Manufacture of (S)-N-(3-((2-((4-((1-acetylpyrrolidin-3-yl)(methyl)amino)phenyl)amino)-5-methoxypyrimidin-4-yl)oxy)phenyl)acrylamide, and Formulations Thereof | February 2021 | August 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17266026 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | February 2021 | May 2024 | Allow | 39 | 1 | 0 | Yes | No |
| 17264744 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | January 2021 | April 2024 | Allow | 38 | 0 | 1 | No | No |
| 17263913 | COMBINATION THERAPY FOR TREATING CANCER | January 2021 | April 2024 | Abandon | 39 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HEASLEY, MEGHAN CHRISTINE.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HEASLEY, MEGHAN CHRISTINE works in Art Unit 1626 and has examined 102 patent applications in our dataset. With an allowance rate of 68.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.
Examiner HEASLEY, MEGHAN CHRISTINE's allowance rate of 68.6% places them in the 23% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HEASLEY, MEGHAN CHRISTINE receive 1.03 office actions before reaching final disposition. This places the examiner in the 13% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by HEASLEY, MEGHAN CHRISTINE is 38 months. This places the examiner in the 11% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +47.1% benefit to allowance rate for applications examined by HEASLEY, MEGHAN CHRISTINE. This interview benefit is in the 93% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 42.0% of applications are subsequently allowed. This success rate is in the 93% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 36.4% of cases where such amendments are filed. This entry rate is in the 47% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 87.5% are granted (fully or in part). This grant rate is in the 94% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.